Neu Health said it’s joining an incubator program that will help it expand its flagship product, a smartphone app that lets people with Parkinson’s disease and dementia track their symptoms from home, in the U.S. market. The UK-based company said it has been selected to join the U.S.
Researchers have uncovered how exposure to a common environmental pesticide may disrupt brain function in ways that contribute to Parkinson’s disease. Exposing rats to rotenone, a pesticide mostly banned in the U.S. and Canada, but still used in lake management, triggered changes in the activation of certain genes in…
Prescribing medication for Parkinson’s disease is not straightforward, but instead is influenced by a wide range of factors and behavioral drivers, according to a new study from Europe that investigated possible reasons for the choices of prescription drugs given by treating clinicians. Beyond clinical guidelines, the researchers found that…
Suppressing the immune system to reduce brain inflammation, a known contributor to Parkinson’s disease progression, may offer a promising new strategy for slowing the disease, early trial results suggest. Specifically, azathioprine, a commonly used drug that suppresses immune activity, reduced motor symptoms and improved cognitive function in people…
Crexont, an extended-release oral formulation of carbidopa and levodopa, significantly improved sleep quality in people with Parkinson’s disease. That’s according to data based on additional analysis of the Phase 3 RISE-PD trial (NCT03670953). The results were detailed in a presentation, “Conversion to CREXONT in…
U.S. researchers have identified a novel way to block a protein known as DLK, or dual leucine-zipper kinase, that may offer a promising strategy to protect neurons from degeneration — which, the team notes, could pave the way for safer and more precise treatments for neurodegenerative conditions like Parkinson’s…
Pretzel Therapeutics has launched a Phase 1 clinical trial to study PX578, a therapy designed to boost the function of mitochondria, the cell’s energy-producing powerhouses, and address conditions caused by faulty energy production. These include rare genetic conditions and neurodegenerative disorders like Parkinson’s and Alzheimer’s. The…
When used as a solo therapy, solengepras (CVN424) — an oral treatment being developed by Cerevance — was seen to lessen both functional and nonmotor symptoms in people with early, untreated Parkinson’s disease. That’s according to top-line results from the Phase 2 ASCEND trial (NCT06006247), which…
Medications commonly used to treat conditions such as high blood pressure, high cholesterol, and pain may delay Parkinson’s disease onset, according to a U.S. study. Analyses found that anti-hypertensives such as adrenergic blockers, cholesterol-lowering statins, and non-steroidal anti-inflammatory drugs (NSAIDs) were strongly associated with later onset disease. In contrast,…
A new positron emission tomography (PET) radiotracer can accurately visualize inflammation within the healthy human brain, a first-in-human study found. By using a marker that binds to COX-2, a key enzyme associated with brain inflammation or neuroinflammation, researchers were able to quantify low levels of this enzyme in healthy individuals.
Get regular updates to your inbox.
